Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 454 N 34th St, Seattle,wa 98103,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://immusoft.com
- Keywords
- rare diseases, B cells, cell therapy.
- HQ
- Seattle, WA
Immusoft Questions
Immusoft's website is http://immusoft.com
Immusoft's LinkedIn profile is https://www.linkedin.com/company/immusoft
Immusoft has
22 employees.
View email and phone details for 22
employees at Immusoft.
Immusoft's industry is
Biotechnology Research
Immusoft's top competitors are
Oisin Biotechnologies,
Papillon Therapeutics,
Nona Biosciences,
Aurion Biotech,
Lift Biosciences,
Quell Therapeutics,
Sensorion,
Kiromic Biopharma, Inc.,
Mongoose Bio Inc.,
Mozart Therapeutics, Inc..
Immusoft's categories are Biotechnology Research
Immusoft's founding year is 2009
